Levosimendan improves renal function in acute decompensated heart failure: Cause and clinical application: Editorial to: "Levosimendan improves renal function in patients with acute decompensated heart failure: Comparison with dobutamine by Yilmaz et al."

Cardiovascular Drugs and Therapy

Volumn 21, Issue 6, 2007, Pages 403-404

  Damman, K ^a   Voors, A A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Acute decompensated heart failure; Central venous pressure; GFR; Levosimendan; Renal function; Venous congestion

Indexed keywords

DOBUTAMINE; LEVOSIMENDAN;

ACUTE HEART FAILURE; BLOOD PRESSURE; CENTRAL VENOUS PRESSURE; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; EDITORIAL; GLOMERULUS FILTRATION RATE; HEART FUNCTION; HEART MUSCLE CONTRACTILITY; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; PRIORITY JOURNAL; URINE VOLUME; VASODILATATION; VENOUS CONGESTION;

ACUTE DISEASE; CARDIOTONIC AGENTS; DOBUTAMINE; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; HYDRAZONES; KIDNEY; PYRIDAZINES;

EID: 36849091435     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-007-6070-y     Document Type: Editorial

References (11)

1. Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail 2007;13:422-30.
2. Damman K, Navis G, Voors AA, et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail 2007;13:599-608.
3. Damman K, Navis G, Smilde TDJ, et al. Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail 2007;9:872-8.
4. Schrier RW. Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor? J Am Coll Cardiol 2006;47:1-8.
5. Yilmaz MB, Yalta K, Yontar C, et al. Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine. Cardiovas Drugs Ther 2007;21 (this issue).
6. Parissis JT, Farmakis D, Nieminen M. Classical inotropes and new cardiac enhancers. Heart Fail Rev 2007;12:149-56.
7. Zemljic G, Bunc M, Yazdanbakhsh AP, Vrtovec B. Levosimendan improves renal function in patients with advanced chronic heart failure awaiting cardiac transplantation. J Card Fail 2007;13:417-21.
8. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002;360:196-202.
9. Moiseyev VS, Poder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002;23:1422-32.
10. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007;297:1883-91.
11. Cleland JG, Freemantle N, Coletta AP, Clark AL. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail 2006;8:105-10.